Biopharmaceuticals
Drug Delivery
Oncology
FDA
News Release - July 11, 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
Source: Halozyme Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.